Risks and benefits of reducing the number of drugs to treat HIV-1 infection

Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy

(2020) Babafemi Taiwo et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients

(2020) Nadia Galizzi et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine

(2020) Joseph Eron et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2)

(2020) F Maggiolo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

(2020) Susan Swindells et al.   NEW ENGLAND JOURNAL OF MEDICINE

No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir

(2020) Arturo Ciccullo et al.   AIDS

“It made me more confident that I have it under control”: Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain

(2020) Wendy Davis et al.   PLoS One

Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV

(2020) Jack Edward Heron et al.   AIDS Research and Therapy

Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV

(2020) Mattia Trunfio et al.   AIDS

Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection

(2020) Cynthia L. Gay et al.   AIDS

Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen

(2020) Jean van Wyk et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Efficacy and safety of switching to dolutegravir with boosted darunavir in virologically suppressed adults with HIV-1: a randomized, open-label, multicenter, phase 3, non-inferiority trial: The DUALIS study

(2020) Christoph D Spinner et al.   Open Forum Infectious Diseases

Tenofovir alafenamide versus tenofovir disoproxil fumarate – an updated meta-analysis of 14,894 patients across 14 trials

(2020) Victoria Pilkington et al.   AIDS

Immunological approaches to HIV cure

(2020) Adam R. Ward et al.   SEMINARS IN IMMUNOLOGY

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

(2019) Alberto Borghetti et al.   BMC INFECTIOUS DISEASES

Simplification of combination antiretroviral therapy (cART) and the brain—a real-life experience

(2019) Gabriele Arendt et al.   JOURNAL OF NEUROVIROLOGY

Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice

(2019) Gianmaria Baldin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Drug–drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment

(2019) Dario Cattaneo et al.   Expert Opinion on Drug Metabolism & Toxicology

Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy

(2019) Jason Gillman et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Does choice of antiretroviral drugs matter for inflammation?

(2019) María del Mar Gutierrez et al.   Expert Review of Clinical Pharmacology

A 24-week pilot study of dual maintenance therapy with raltegravir plus lamivudine

(2019) Elisa de Lazzari et al.   AIDS

Genital Human Immunodeficiency Virus–1 RNA and DNA Shedding in Virologically Suppressed Individuals Switching From Triple- to Dual- or Monotherapy: Pooled Results From 2 Randomized, Controlled Trials

(2019) Laurent Hocqueloux et al.   CLINICAL INFECTIOUS DISEASES

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients

(2019) Matthew Radford et al.   AIDS

Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice

(2019) Arturo Ciccullo et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients

(2019) Gianmaria Baldin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.

(2019) Andrea Giacomelli et al.   ANTIVIRAL RESEARCH

Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection

(2019) Lesley J. Scott   DRUGS

Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care

(2019) Virginia A Triant et al.   JOURNAL OF INFECTIOUS DISEASES

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

(2018) Ignacio Pérez-Valero et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy

(2018) Simone Belmonti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial

(2018) Massimiliano Fabbiani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study

(2018) Roberta Gagliardini et al.   Open Forum Infectious Diseases

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials

(2018) D Hagins et al.   HIV MEDICINE

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2018) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients

(2018) Alicia Gutierrez-Valencia et al.   PLoS One

Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial

(2017) Francesca Lombardi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

(2016) Hans-Jürgen Stellbrink et al.   AIDS

The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir

(2016) Maureen Oliveira et al.   AIDS

Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study

(2016) Sarah Lilian Pett et al.   CLINICAL INFECTIOUS DISEASES

Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: Table 1.

(2016) A. Borghetti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

(2016) J. A. Perez-Molina et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

(2016) Joel E Gallant et al.   Lancet HIV

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

(2015) Michael P. Girouard et al.   CLINICAL INFECTIOUS DISEASES

Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054)

(2015) Benoit Trottier et al.   HIV CLINICAL TRIALS

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

(2015) Paul E Sax et al.   LANCET

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

(2015) José R Arribas et al.   LANCET INFECTIOUS DISEASES

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

(2014) François Raffi et al.   LANCET

Bone Alterations Associated with HIV

(2014) Amy H. Warriner et al.   Current HIV/AIDS Reports

A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study

(2012) Ighovwerha Ofotokun et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study

(2012) Jacques Reynes et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

(2012) Michael J. Kozal et al.   HIV CLINICAL TRIALS